<DOC>
	<DOC>NCT02461953</DOC>
	<brief_summary>This study is a prospective, randomized, controlled multicenter clinical study. The aim of the study is to investigate whether the combination of maintenance hemodialysis (MHD) with hemoperfusion (HP) could improve the clearance rate of middle and large molecule uremic toxins so as to improve the quality of life of MHD patients and reduce their mortality rate.</brief_summary>
	<brief_title>Combination of Hemodialysis With Hemoperfusion：A Clinical Study</brief_title>
	<detailed_description />
	<criteria>1. Age≥18, male or female 2. Maintenance hemodialysis duration＞3 months 3. Regular hemodialysis,3 times a week,4 hours per session 4. Vascular access unlimited 5. iPTH≥300pg/ml 6. Sign the written informed consent 1. Allergic to dialysis equipment 2. PLT＜60×10^9/L 3. Blood flow＜200ml/min 4. Serum albumin＜30g/L 5. Kt/V＜1.2 6. iPTH＞800pg/ml 7. Hemodiafiltration 8. Coagulation disorder, severe bleeding tendency, with active bleeding 9. Severe hypotension, severe cardiopulmonary insufficiency 10. Under other drug trial 11. Acute infection, severe heart, lung, liver, nervous diseases, malignant tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>hemodialysis</keyword>
	<keyword>hemoperfusion</keyword>
	<keyword>quality of life</keyword>
</DOC>